GlycoMimetics (NASDAQ:GLYC – Get Free Report) is set to announce its earnings results before the market opens on Wednesday, March 27th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.
GlycoMimetics Stock Up 1.7 %
GLYC stock opened at $2.93 on Monday. The stock has a market capitalization of $188.66 million, a PE ratio of -4.65 and a beta of 2.19. The firm has a 50 day moving average of $3.00 and a 200 day moving average of $2.15. GlycoMimetics has a 52 week low of $1.11 and a 52 week high of $3.53.
Institutional Investors Weigh In On GlycoMimetics
Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC acquired a new stake in GlycoMimetics in the 1st quarter valued at $30,000. XTX Topco Ltd acquired a new stake in GlycoMimetics during the 2nd quarter worth $52,000. Charles Schwab Investment Management Inc. acquired a new stake in GlycoMimetics during the 4th quarter worth $68,000. Jane Street Group LLC acquired a new stake in GlycoMimetics during the 4th quarter worth $75,000. Finally, Virtu Financial LLC acquired a new stake in GlycoMimetics during the 4th quarter worth $81,000. Institutional investors and hedge funds own 55.36% of the company’s stock.
Analyst Upgrades and Downgrades
View Our Latest Stock Report on GlycoMimetics
GlycoMimetics Company Profile
GlycoMimetics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML.
Recommended Stories
- Five stocks we like better than GlycoMimetics
- Investing in Construction Stocks
- Nvidia’s AI Tech Part of Novo Nordisk’s New Supercomputer
- How to Use the MarketBeat Stock Screener
- MarketBeat Week in Review – 3/18 – 3/22
- What is the S&P/TSX Index?
- KB Home: Building on Strong Foundations During Volatile Times
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.